Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK rearrange ALK T1151R |
Therapy | Ceritinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK rearrange ALK T1151R | lung adenocarcinoma | predicted - resistant | Ceritinib | Case Reports/Case Series | Actionable | In a clinical case study, ALK T1151R was identified on post-progression biopsy in a patient with lung adenocarcinoma harboring an ALK rearrangement who had been on Zykadia (ceritinib) treatment for 6 months (PMID: 31027750). | 31027750 |
PubMed Id | Reference Title | Details |
---|---|---|
(31027750) | Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib. | Full reference... |